Categories AlphaGraphs, Earnings, Health Care
BMY Earnings: Everything you need to know about Bristol Myers’ Q4 results
Bristol Myers Squibb (NYSE: BMY) on Thursday announced results for the fourth quarter of 2022, reporting lower earnings and revenues.
The pharma company reported revenues of $11.4 billion for the fourth quarter, down 5% from the same period a year ago. Net earnings attributable to the company were $2.02 billion, or $0.95 per share, compared to $2.37 billion, or $1.07 per share a year earlier. Adjusted earnings edged down by 1% to $1.82 per share.
“With a younger and more diversified portfolio, promising mid-to-late-stage registrational assets, and a deep early-stage pipeline, I am confident that the company is well-positioned for multiple waves of innovation that will support long-term growth,” said the company’s CEO Giovanni Caforio.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode
Over the years, Johnson & Johnson (NYSE: JNJ) has remained a dominant player in the medical industry, benefitting from its unique business model and growth strategy focused on constant innovation.
Key takeaways from PepsiCo’s Q3 2024 earnings report
Shares of PepsiCo, Inc. (NASDAQ: PEP) gained over 1% on Tuesday even though the company delivered mixed results for the third quarter of 2024 and lowered its guidance for the
PEP Earnings: All you need to know about PepsiCo’s Q3 2024 earnings results
PepsiCo, Inc. (NASDAQ: PEP) reported its third quarter 2024 earnings results today. Net revenue dipped 0.6% to $23.3 billion compared to the same period a year ago. Organic revenue growth
